EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine - Pharmaceutical Technology

AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN). AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN). Aquipta was first approved in Europe in 2023. Credit: peterschreiber.media/Shutterstock.com. On June 27, at the 12 th Congress of the European Academy of Neurology (EAN) 2026, three e-posters with results from the Phase III ECLIPSE trial (NCT06241313) of AbbVie’s Aquipta (atogepant) were presented. ECLIPSE was a randomised, double-blind, placebo-controlled, Phase III trial evaluating Aquipta as an…

Source: Pharmaceutical Technology